Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.85B |
| 2 |
Tesla
TSLA
|
+$1.78B |
| 3 |
Apple
AAPL
|
+$1.57B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$1.49B |
| 5 |
Mastercard
MA
|
+$1.09B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$1.3B |
| 2 |
Phillips 66
PSX
|
+$650M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$475M |
| 4 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$432M |
| 5 |
NRG Energy
NRG
|
+$387M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.59% |
| 2 | Financials | 9.21% |
| 3 | Consumer Discretionary | 7.33% |
| 4 | Healthcare | 5.59% |
| 5 | Communication Services | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ODV
4501
DELISTED
Osisko Development Corp
ODV
| $44.6K | ﹤0.01% |
29,930
| – | – |
|
4502
iShares Core US Aggregate Bond ETF
AGG
$137B
| $44.5K | ﹤0.01% |
450
| – | – |
|
|
NVBU
4503
AllianzIM U.S. Equity Buffer15 Uncapped Nov ETF
NVBU
$34.6M
| $44.5K | ﹤0.01% |
+1,793
| New | +$46K |
|
4504
Innovator US Equity Accelerated Plus ETF January
XTJA
$20.6M
| $44.4K | ﹤0.01% |
1,651
+284
| +21% | +$7.91K |
|
4505
Werewolf Therapeutics
HOWL
$17.2M
| $44.1K | ﹤0.01% |
45,361
-14,387
| -24% | -$18.8K |
|
|
SHCO
4506
DELISTED
Soho House & Co
SHCO
| $44.1K | ﹤0.01% |
7,128
-1,530
| -18% | -$11.1K |
|
4507
X4 Pharmaceuticals
XFOR
$375M
| $43.8K | ﹤0.01% |
6,169
-2,703
| -30% | -$37.2K |
|
4508
Purple Innovation
PRPL
$35.3M
| $43.5K | ﹤0.01% |
2,291
-1,134
| -33% | -$26.1K |
|
4509
Veritone
VERI
$101M
| $43.4K | ﹤0.01% |
18,673
-18,863
| -50% | -$54.7K |
|
4510
Roadzen
RDZN
$97.2M
| $43.1K | ﹤0.01% |
41,468
-15,558
| -27% | -$20.9K |
|
4511
Fractyl Health
GUTS
$109M
| $42.7K | ﹤0.01% |
35,907
-17,019
| -32% | -$27.2K |
|
4512
Critical Metals Corp
CRML
$806M
| $42.7K | ﹤0.01% |
30,737
+17,861
| +139% | +$81.4K |
|
|
CRESY
4513
Cresud
CRESY
$795M
| $42.7K | ﹤0.01% |
3,899
| – | – |
|
|
RAPT
4514
DELISTED
RAPT Therapeutics
RAPT
| $42.7K | ﹤0.01% |
4,372
-1,278
| -23% | -$12.6K |
|
|
ZOCT
4515
Innovator Equity Defined Protection ETF - 1 Yr October
ZOCT
$105M
| $42.5K | ﹤0.01% |
1,691
+1,591
| +1,591% | +$40.4K |
|
4516
Artesian Resources
ARTNA
$355M
| $42.4K | ﹤0.01% |
+1,299
| New | +$40.7K |
|
4517
Ramaco Resources Class B
METCB
$425M
| $42.4K | ﹤0.01% |
6,283
-2,749
| -30% | -$23.1K |
|
|
AKYA
4518
DELISTED
Akoya BioSciences
AKYA
| $42K | ﹤0.01% |
30,238
-13,243
| -30% | -$29K |
|
4519
iShares S&P Small-Cap 600 Value ETF
IJS
$8.12B
| $41.9K | ﹤0.01% |
430
| – | – |
|
|
MRSN
4520
DELISTED
Mersana Therapeutics
MRSN
| $41.9K | ﹤0.01% |
4,869
-2,439
| -33% | -$37.6K |
|
4521
Sasol
SSL
$7.5B
| $41.9K | ﹤0.01% |
9,900
+479
| +5% | +$2.17K |
|
4522
Alto Ingredients
ALTO
$369M
| $41.8K | ﹤0.01% |
36,634
-52,438
| -59% | -$81.1K |
|
4523
Tevogen Inc. Common Stock
TVGN
$29.7M
| $41.1K | ﹤0.01% |
761
-151
| -17% | -$9.93K |
|
4524
LiveWire
LVWR
$371M
| $39.6K | ﹤0.01% |
19,819
-9,024
| -31% | -$26.3K |
|
|
AGEN
4525
Agenus
AGEN
$312M
| $39.6K | ﹤0.01% |
26,302
-6,435
| -20% | -$18.5K |
|
Similar funds
Barclays's Q1 2025 Portfolio in Review
As of Q1 2025, Barclays held 5,710 positions worth $353B, down 1.2% from $357B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Barclays deployed $16.5B of net new capital in Q1 2025, opening 439 new positions and adding to 1,449 existing holdings. Its largest new stake was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Honeywell, an estimated $1.3B trimmed.
- Barclays's largest Q1 2025 buy was JPMorgan BetaBuilders USD High Yield Corporate Bond ETF: 318,453 shares worth $14.7M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $3.85B increase.
- Barclays's biggest Q1 2025 reduction was Honeywell, cutting an estimated $1.3B.
- Barclays fully exited Smartsheet Inc. in Q1 2025, selling an estimated $45.7M.
- Barclays's ten largest holdings make up 37% of its $353B portfolio in Q1 2025.
- Barclays opened 439 new positions and closed 470 in Q1 2025.
- Barclays's portfolio value fell 1.2% quarter-over-quarter to $353B.
Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.